Bo Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bo Zhang has a total of 97 co-authors. Here are the top co-authors by number of shared publications:
He Huang
Department of Dermatology, The Fourth Affiliated Hospital of Soochow University (Suzhou Dushu Lake Hospital; Medical Center of Soochow University), Suzhou, Jiangsu, China; Department of Dermatology of First Affiliated Hospital, and Institute of Dermatology, Anhui Medical University, Hefei, Anhui, China
7 shared publicationsWeiran Li
Department of Dermatology of First Affiliated Hospital, and Institute of Dermatology, Anhui Medical University, Hefei, Anhui, China
6 shared publicationsXuejun Zhang
Department of Dermatology, The Fourth Affiliated Hospital of Soochow University (Suzhou Dushu Lake Hospital; Medical Center of Soochow University), Suzhou, Jiangsu, China; Department of Dermatology of First Affiliated Hospital, and Institute of Dermatology, Anhui Medical University, Hefei, Anhui, China; Department of Dermatology, Dermatology Center in Bo ao Super Hospital, Qionghai, Hainan, China
6 shared publicationsYujun Sheng
Department of Dermatology, China-Japan Friendship Hospital, Beijing, China
5 shared publicationsDawei Duan
Department of Dermatology of First Affiliated Hospital, and Institute of Dermatology, Anhui Medical University, Hefei, Anhui, China
4 shared publicationsHequn Huang
Department of Dermatology of First Affiliated Hospital, and Institute of Dermatology, Anhui Medical University, Hefei, Anhui, China
4 shared publications
Latest Publications
- Open Access
- 27 February 2026
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 94 (6) , 1875-1876
Clinical efficacy and safety analysis of 1.5% ruxolitinib cream in the treatment of facial vitiligo in adolescents: A retrospective study of 74 cases
- 27 February 2026
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 94 (6) , 1875-1876
Open AccessClinical efficacy and safety analysis of 1.5% ruxolitinib cream in the treatment of facial vitiligo in adolescents: A retrospective study of 74 cases
- 23 February 2026
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 94 (6) , 1867-1869
Targeted synergy for vitiligo in refractory areas: A real-world study of ruxolitinib cream combined with 308-nm excimer lamp
- 23 February 2026
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 94 (6) , 1867-1869
Targeted synergy for vitiligo in refractory areas: A real-world study of ruxolitinib cream combined with 308-nm excimer lamp
- Open Access
- 1 January 2026
- Published by Wiley in Dermatologic Therapy
- Vol. 2026 (1) , 9941211
Tildrakizumab for Systemic‐Treatment‐Eligible Plaque Psoriasis: A Retrospective Real‐World Study in Chinese Patients
Background: Real‐world data on tildrakizumab in Chinese patients with plaque psoriasis remain limited, particularly in patients treated in routine practice based on systemic treatment eligibility rather than trial‐style severity thresholds. Objective: To assess the effectiveness and safety of tildrakizumab in Chinese patients with plaque psoriasis over a 28‐week follow‐up period. Methods: Adults with plaque psoriasis eligible for systemic therapy were enrolled in this multicenter, retrospective, observational study. Psoriasis area and severity index (PASI), body surface area (BSA), and dermatology life quality index (DLQI) were evaluated at baseline, Week 16, and Week 28. Adverse events (AEs) were collected simultaneously. Results: A total of 59 patients were included (72.9% male, median age 39.0 years), with baseline PASI, BSA, and DLQI of 6.0 ± 6.3, 8.3 ± 10.4%, and 8.2 ± 7.2, respectively. At Week 16, PASI 75, PASI 90, and PASI 100 responses were achieved in 64.3%, 42.9%, and 38.1% of evaluable patients, respectively; corresponding rates at Week 28 were 79.5%, 70.5%, and 54.5%. Absolute PASI targets (PASI ≤ 3 and PASI ≤ 1) were achieved by 90.5% and 66.7% at Week 16, and 97.7% and 81.8% at Week 28, respectively. Mean PASI, BSA, and DLQI all significantly improved from baseline at follow‐up visits. At Week 28, 77.5% of patients achieved DLQI 0/1. In subgroup analyses, biologic‐naïve patients showed higher response rates than biologic‐experienced patients at Week 28, although baseline disease severity differed between groups. AEs occurred in 6.8% of patients and were mild. No patients with latent tuberculosis encountered reactivation. Conclusions: In this real‐world study, tildrakizumab demonstrated significant effectiveness in Chinese patients with plaque psoriasis eligible for systemic therapy. No new safety signals were observed within the 28‐week follow‐up period.
- 1 January 2026
- Published by Wiley in Dermatologic Therapy
- Vol. 2026 (1) , 9941211
Open AccessTildrakizumab for Systemic‐Treatment‐Eligible Plaque Psoriasis: A Retrospective Real‐World Study in Chinese Patients
Background: Real‐world data on tildrakizumab in Chinese patients with plaque psoriasis remain limited, particularly in patients treated in routine practice based on systemic treatment eligibility rather than trial‐style severity thresholds. Objective: To assess the effectiveness and safety of tildrakizumab in Chinese patients with plaque psoriasis over a 28‐week follow‐up period. Methods: Adults with plaque psoriasis eligible for systemic therapy were enrolled in this multicenter, retrospective, observational study. Psoriasis area and severity index (PASI), body surface area (BSA), and dermatology life quality index (DLQI) were evaluated at baseline, Week 16, and Week 28. Adverse events (AEs) were collected simultaneously. Results: A total of 59 patients were included (72.9% male, median age 39.0 years), with baseline PASI, BSA, and DLQI of 6.0 ± 6.3, 8.3 ± 10.4%, and 8.2 ± 7.2, respectively. At Week 16, PASI 75, PASI 90, and PASI 100 responses were achieved in 64.3%, 42.9%, and 38.1% of evaluable patients, respectively; corresponding rates at Week 28 were 79.5%, 70.5%, and 54.5%. Absolute PASI targets (PASI ≤ 3 and PASI ≤ 1) were achieved by 90.5% and 66.7% at Week 16, and 97.7% and 81.8% at Week 28, respectively. Mean PASI, BSA, and DLQI all significantly improved from baseline at follow‐up visits. At Week 28, 77.5% of patients achieved DLQI 0/1. In subgroup analyses, biologic‐naïve patients showed higher response rates than biologic‐experienced patients at Week 28, although baseline disease severity differed between groups. AEs occurred in 6.8% of patients and were mild. No patients with latent tuberculosis encountered reactivation. Conclusions: In this real‐world study, tildrakizumab demonstrated significant effectiveness in Chinese patients with plaque psoriasis eligible for systemic therapy. No new safety signals were observed within the 28‐week follow‐up period.
- 10 November 2025
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (8)
Topical ruxolitinib ± oral baricitinib in the treatment of active non‐segmental vitiligo: A retrospective analysis
- 10 November 2025
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (8)
Topical ruxolitinib ± oral baricitinib in the treatment of active non‐segmental vitiligo: A retrospective analysis
- 10 November 2025
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 146 (6) , 1571-1577
Beyond depigmentation: A cross-sectional study of 5227 Chinese patients with vitiligo
- 10 November 2025
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 146 (6) , 1571-1577
Beyond depigmentation: A cross-sectional study of 5227 Chinese patients with vitiligo
- 16 September 2025
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 94 (1) , 312-314
Efficacy of ruxolitinib cream at different body sites in Chinese patients with nonsegmental vitiligo
- 16 September 2025
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 94 (1) , 312-314
Efficacy of ruxolitinib cream at different body sites in Chinese patients with nonsegmental vitiligo
- 3 April 2025
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 145 (10) , 2606-2609.e6
Transcriptome and Chromatin Landscape Changes Associated with Pathogenesis of Psoriasis in Memory T Helper and Memory Regulatory T Cells
- 3 April 2025
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 145 (10) , 2606-2609.e6
Transcriptome and Chromatin Landscape Changes Associated with Pathogenesis of Psoriasis in Memory T Helper and Memory Regulatory T Cells
- 1 November 2020
- Vol. 71 (6) , 367-375
Detection and Analysis of Ceramide in Skin and Blood in a Healthy Chinese Population
To explore the significance of ceramide in the skin barrier and its potential utility within the cosmetics industry, an accurate and high-speed method was used to detect the types of ceramides in the skin and blood of a healthy Chinese population. Forearm cortical skin stratum corneum samples were obtained from four healthy subjects using a noninvasive method. In addition, these subjects were collected intravenously to obtain blood samples. Ceramides were detected in skin and blood samples using high-performance liquid chromatography coupled with specialized high-resolution Fourier Transform mass spectrometry machine. Data were analyzed using full-flow lipid analysis software. Peaks representing ceramides were detected in all skin samples and some blood samples. The results show that ceramides in skin are predominantly long-chain ceramides, but mainly short-chain in the blood. Simple and fast qualitative and quantitative analysis of ceramide in the skin and blood provides a basis for the precise addition of ceramide in future skin care products and the metabolic regulation and prevention of various diseases.
- 1 November 2020
- Vol. 71 (6) , 367-375
Detection and Analysis of Ceramide in Skin and Blood in a Healthy Chinese Population
To explore the significance of ceramide in the skin barrier and its potential utility within the cosmetics industry, an accurate and high-speed method was used to detect the types of ceramides in the skin and blood of a healthy Chinese population. Forearm cortical skin stratum corneum samples were obtained from four healthy subjects using a noninvasive method. In addition, these subjects were collected intravenously to obtain blood samples. Ceramides were detected in skin and blood samples using high-performance liquid chromatography coupled with specialized high-resolution Fourier Transform mass spectrometry machine. Data were analyzed using full-flow lipid analysis software. Peaks representing ceramides were detected in all skin samples and some blood samples. The results show that ceramides in skin are predominantly long-chain ceramides, but mainly short-chain in the blood. Simple and fast qualitative and quantitative analysis of ceramide in the skin and blood provides a basis for the precise addition of ceramide in future skin care products and the metabolic regulation and prevention of various diseases.
- 25 April 2020
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 20 (1) , 243-248
Correlation analysis between advanced glycation end products detected noninvasively and skin aging factors
Objective: To investigate the correlation between advanced glycation end products (AGEs) and skin elasticity or blood perfusion values in healthy people of different age groups and to evaluate the relationship between noninvasive detection of AGEs and age or skin aging.Methods: One hundred and two healthy people were enrolled and grouped into groups of 20 years old. Group I: 19‐40 years old; Group II: 41‐60 years old; Group III: 61‐80 years old. Noninvasive techniques such as fluorescence spectroscopy and laser speckle flowmetry were used to detect AGEs levels, local skin perfusion value, and skin elasticity in skin tissue at all age groups.Result: The AGEs in the skin increased with age, and the difference between the three age groups was statistically significant (P < .05).There was no significant difference in gender between AGEs (P > .05).There was no significant relationship between AGEs and skin elasticity or blood perfusion value in the Group I; there was a low correlation between AGEs and skin elasticity in the 41‐60 years age group (r < .4,P < .05). The level of AGEs in the elderly over 60 years was significantly positively correlated with skin elasticity and blooding perfusion value (r > .4,P < .05).Conclusion: There is a significant correlation between AGEs and age or skin aging indicators. As the age increasing, the level of AGEs increases obviously, which can be used as a potential noninvasive tool for detecting skin aging.
- 25 April 2020
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 20 (1) , 243-248
Correlation analysis between advanced glycation end products detected noninvasively and skin aging factors
Objective: To investigate the correlation between advanced glycation end products (AGEs) and skin elasticity or blood perfusion values in healthy people of different age groups and to evaluate the relationship between noninvasive detection of AGEs and age or skin aging.Methods: One hundred and two healthy people were enrolled and grouped into groups of 20 years old. Group I: 19‐40 years old; Group II: 41‐60 years old; Group III: 61‐80 years old. Noninvasive techniques such as fluorescence spectroscopy and laser speckle flowmetry were used to detect AGEs levels, local skin perfusion value, and skin elasticity in skin tissue at all age groups.Result: The AGEs in the skin increased with age, and the difference between the three age groups was statistically significant (P < .05).There was no significant difference in gender between AGEs (P > .05).There was no significant relationship between AGEs and skin elasticity or blood perfusion value in the Group I; there was a low correlation between AGEs and skin elasticity in the 41‐60 years age group (r < .4,P < .05). The level of AGEs in the elderly over 60 years was significantly positively correlated with skin elasticity and blooding perfusion value (r > .4,P < .05).Conclusion: There is a significant correlation between AGEs and age or skin aging indicators. As the age increasing, the level of AGEs increases obviously, which can be used as a potential noninvasive tool for detecting skin aging.
- 1 April 2019
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 139 (4) , 957-960
Meta-Analysis Identifies Major Histocompatiblity Complex Loci in or Near HLA-DRB1, HLA-DQA1, HLA-C as Associated with Leprosy in Chinese Han Population
- 1 April 2019
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 139 (4) , 957-960
Meta-Analysis Identifies Major Histocompatiblity Complex Loci in or Near HLA-DRB1, HLA-DQA1, HLA-C as Associated with Leprosy in Chinese Han Population